PWPS
MLYS icon

Pinnacle Wealth Planning Services’s Mineralys Therapeutics MLYS Stock Holding History

Pinnacle Wealth Planning Services’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.62K Hold
355
– – ﹤0.01% 2019
2025
Q4 		$12.9K Buy
+355
New +$14.2K ﹤0.01% 1913

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Pinnacle Wealth Planning Services's MLYS Position: Q1 2026 in Review

Pinnacle Wealth Planning Services held its Mineralys Therapeutics (MLYS) position steady in Q1 2026 at 355 shares worth $9.62K. The position accounts for ﹤0.01% of the portfolio, ranked #2019.

Pinnacle Wealth Planning Services first reported a position in MLYS in Q4 2025 and has held it in 2 quarters since. The position peaked at $12.9K in Q4 2025. 214 funds tracked by Wall St. Rank hold MLYS as of Q1 2026.

  • Pinnacle Wealth Planning Services held 355 shares of Mineralys Therapeutics worth $9.62K as of Q1 2026.
  • Pinnacle Wealth Planning Services left its Mineralys Therapeutics share count unchanged in Q1 2026.
  • Mineralys Therapeutics made up ﹤0.01% of Pinnacle Wealth Planning Services's portfolio in Q1 2026, its #2019 holding.
  • Pinnacle Wealth Planning Services first reported a position in Mineralys Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Pinnacle Wealth Planning Services's Mineralys Therapeutics position peaked at $12.9K in Q4 2025.
  • 214 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q1 2026.

Based on Pinnacle Wealth Planning Services's 13F filing for Q1 2026, filed 11 May 2026.